X4 Pharmaceuticals (XFOR) Intangibles (2019 - 2025)
X4 Pharmaceuticals (XFOR) reported Intangibles of $9.3 million for Q4 2025, down 7.0% on a YoY basis from $10.0 million in Q4 2024, and down 1.06% quarter-over-quarter from $9.4 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Intangibles (2019 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Intangibles for 3 years, with the latest figure at $9.3 million in Q4 2025.
- For the quarter ending Q4 2025, Intangibles fell 7.0% year-over-year to $9.3 million; the trailing twelve-month figure through Dec 2025 stood at $9.3 million (down 7.0% YoY), and the FY2025 full-year result was $9.3 million, down 7.0% from the prior year.
- Intangibles for Q4 2025 stood at $9.3 million, down from $9.4 million in the prior quarter.
- The five-year high for Intangibles was $10.4 million in Q2 2024, with the low at $9.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 7.73 Mn |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.30 Mn |
| Sep 30, 2025 | 9.40 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | 9.81 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 10.20 Mn |
| Jun 30, 2024 | 10.40 Mn |
| Jun 30, 2019 | 4.90 Mn |
| Mar 31, 2019 | 4.90 Mn |